<DOC>
	<DOCNO>NCT00306189</DOCNO>
	<brief_summary>The primary objective study assess effect AMG 162 ( denosumab ) treatment lumbar spine BMD month 12 safety profile across dose range test ( 14 , 60 100 mg SC every 6 month ) Japanese postmenopausal osteoporotic subject compare treat placebo 12 month .</brief_summary>
	<brief_title>A Randomized , Double-blind , Placebo-controlled , Dose Response Study AMG 162 ( Denosumab ) Japanese Postmenopausal Osteoporotic Subjects</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Denosumab</mesh_term>
	<criteria>Ambulatory postmenopausal woman . BMD value ( g/cm2 , Hologic ) must lower 0.714 lumbar spine , 0.515 femoral neck , 0.588 total hip . BMD value must lower 0.535 lumbar spine , 0.406 femoral neck 0.478 total hip . Oral bisphosphonate treatment , PTH PTH derivative use within last 12 month administration antiosteoporotic treatment within last 3 month initial administration investigational product . History hypocalcemia . More two moderate vertebral fracture severe vertebral fracture .</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>RANKL</keyword>
	<keyword>RANK</keyword>
	<keyword>denosumab</keyword>
	<keyword>AMG 162</keyword>
	<keyword>osteoporosis</keyword>
	<keyword>bone turnover</keyword>
	<keyword>bone mineral density</keyword>
	<keyword>Japanese</keyword>
</DOC>